Acorah Software Products - Accounts Production 19.3.550 false true false true No description of principal activity 11 November 2024 30 November 2025 30 November 2025 16071513 Mr Paul Travis iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 16071513 2024-11-10 16071513 2025-11-30 16071513 2024-11-11 2025-11-30 16071513 frs-core:CurrentFinancialInstruments 2025-11-30 16071513 frs-bus:PrivateLimitedCompanyLtd 2024-11-11 2025-11-30 16071513 frs-bus:FilletedAccounts 2024-11-11 2025-11-30 16071513 frs-bus:Micro-entities 2024-11-11 2025-11-30 16071513 frs-bus:AuditExempt-NoAccountantsReport 2024-11-11 2025-11-30 16071513 frs-bus:Director1 2024-11-11 2025-11-30
Registered number: 16071513
Oncologylabs.Com Ltd
Unaudited Financial Statements
For the Period 11 November 2024 to 30 November 2025
Oncologylabs.Com Ltd
Balance Sheet
As At 30 November 2025
Balance Sheet
Registered number: 16071513

| 30 November 2025
--- | ---
|  | £
Current assets |  | 82,141
Creditors: Amounts Falling Due Within One Year |  | (18,536 )
NET CURRENT ASSETS |  | 63,605
TOTAL ASSETS LESS CURRENT LIABILITIES |  | 63,605
Accruals and deferred income |  | (900 )
NET ASSETS |  | 62,705
CAPITAL AND RESERVES |  | 62,705

## Notes

1. General Information
Oncologylabs.Com Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 16071513 . The registered office is 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ.
2. Average Number of Employees
Average number of employees, including directors, during the period was: 1
1
For the period ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board

Mr Paul Travis Director
05/08/2026